Last reviewed · How we verify
PCV10 and DTaP
PCV10 and DTaP is a combination vaccine that stimulates the immune system to produce antibodies against pneumococcal serotypes and diphtheria, tetanus, and pertussis toxins.
PCV10 and DTaP is a combination vaccine that stimulates the immune system to produce antibodies against pneumococcal serotypes and diphtheria, tetanus, and pertussis toxins. Used for Prevention of invasive pneumococcal disease caused by serotypes in PCV10, Prevention of diphtheria, tetanus, and pertussis in infants and children.
At a glance
| Generic name | PCV10 and DTaP |
|---|---|
| Also known as | Synflorix |
| Sponsor | KEMRI-Wellcome Trust Collaborative Research Program |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
PCV10 (pneumococcal conjugate vaccine) contains polysaccharide antigens from 10 serotypes of Streptococcus pneumoniae conjugated to a protein carrier, eliciting both T-cell and B-cell responses. DTaP (diphtheria, tetanus, acellular pertussis) contains inactivated toxins and acellular pertussis antigens that trigger protective antibody production against these three bacterial pathogens. Together, the combination vaccine provides immunological protection against invasive pneumococcal disease and pertussis-related illnesses.
Approved indications
- Prevention of invasive pneumococcal disease caused by serotypes in PCV10
- Prevention of diphtheria, tetanus, and pertussis in infants and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
Key clinical trials
- Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe (PHASE3)
- PCV10 Reactogenicity and Immunogenicity Study - Malindi (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PCV10 and DTaP CI brief — competitive landscape report
- PCV10 and DTaP updates RSS · CI watch RSS
- KEMRI-Wellcome Trust Collaborative Research Program portfolio CI